Treatment of epidermal growth factor receptor inhibitor-induced severe paronychia with pyogenic granuloma-like lesions with topical betaxolol: an open-label observation study.
Administration, Topical
Adrenergic beta-1 Receptor Antagonists
/ administration & dosage
Adult
Aged
Aged, 80 and over
Antineoplastic Agents
/ adverse effects
Betaxolol
/ administration & dosage
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Dermatologic Agents
/ administration & dosage
ErbB Receptors
/ antagonists & inhibitors
Female
Granuloma, Pyogenic
/ chemically induced
Humans
Lung Neoplasms
/ drug therapy
Male
Middle Aged
Paronychia
/ chemically induced
Protein Kinase Inhibitors
/ adverse effects
Wound Healing
/ drug effects
Journal
International journal of dermatology
ISSN: 1365-4632
Titre abrégé: Int J Dermatol
Pays: England
ID NLM: 0243704
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
received:
02
03
2019
revised:
30
07
2019
accepted:
31
10
2019
pubmed:
26
11
2019
medline:
29
9
2020
entrez:
26
11
2019
Statut:
ppublish
Résumé
Paronychia is a common adverse event caused by epidermal growth factor receptor (EGFR) inhibitors. However, high rates of post-treatment discomfort, infection, recurrence, and increased time to return to work have been noted after nail plate avulsion for EGFR inhibitor-induced paronychia. Furthermore, poor wound healing and malnutrition were common conditions found in cancer patients. The aim of this study is to find an effective, pain-relieving, and noninvasive treatment for patients with severe paronychia induced by EGFR inhibitors. Data from a series of 35 non-small cell lung cancer cases suffering from EGFR inhibitor-induced paronychia with pyogenic granuloma-like lesions of digits treated with betaxolol 0.25% ophthalmic solution once daily were collected and analyzed. Of the 35 patients suffering from grade 2 or 3 paronychia with pyogenic granuloma-like lesions induced by EGFR inhibitors, 34 (97.1%) demonstrated complete resolution and only one (2.9%) had partial resolution after 12 weeks of topical betaxolol treatment. The grading of paronychia according to the Common Terminology Criteria for Adverse Events decreased from an average of 2.29 to 0.63 after 4 weeks of treatment (P = 5.55 × 10 Betaxolol 0.25% ophthalmic solution is an effective, safe, and pain-relieving treatment for patients suffering from EGFR inhibitor-induced paronychia with pyogenic granuloma-like lesions and deep fissures.
Sections du résumé
BACKGROUND
BACKGROUND
Paronychia is a common adverse event caused by epidermal growth factor receptor (EGFR) inhibitors. However, high rates of post-treatment discomfort, infection, recurrence, and increased time to return to work have been noted after nail plate avulsion for EGFR inhibitor-induced paronychia. Furthermore, poor wound healing and malnutrition were common conditions found in cancer patients. The aim of this study is to find an effective, pain-relieving, and noninvasive treatment for patients with severe paronychia induced by EGFR inhibitors.
METHODS
METHODS
Data from a series of 35 non-small cell lung cancer cases suffering from EGFR inhibitor-induced paronychia with pyogenic granuloma-like lesions of digits treated with betaxolol 0.25% ophthalmic solution once daily were collected and analyzed.
RESULTS
RESULTS
Of the 35 patients suffering from grade 2 or 3 paronychia with pyogenic granuloma-like lesions induced by EGFR inhibitors, 34 (97.1%) demonstrated complete resolution and only one (2.9%) had partial resolution after 12 weeks of topical betaxolol treatment. The grading of paronychia according to the Common Terminology Criteria for Adverse Events decreased from an average of 2.29 to 0.63 after 4 weeks of treatment (P = 5.55 × 10
CONCLUSION
CONCLUSIONS
Betaxolol 0.25% ophthalmic solution is an effective, safe, and pain-relieving treatment for patients suffering from EGFR inhibitor-induced paronychia with pyogenic granuloma-like lesions and deep fissures.
Substances chimiques
Adrenergic beta-1 Receptor Antagonists
0
Antineoplastic Agents
0
Dermatologic Agents
0
Protein Kinase Inhibitors
0
ErbB Receptors
EC 2.7.10.1
Betaxolol
O0ZR1R6RZ2
Types de publication
Case Reports
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
326-332Informations de copyright
© 2019 The International Society of Dermatology.
Références
Balagula Y, Garbe C, Myskowski PL, et al. Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors. Int J Dermatol 2011; 50: 129-146.
Garden BC, Wu S, Lacouture ME. The risk of nail changes with epidermal growth factor receptor inhibitors: a systematic review of the literature and meta-analysis. J Am Acad Dermatol 2012; 67: 400-408.
Melosky B, Leighl NB, Rothenstein J, et al. Management of egfr tki-induced dermatologic adverse events. Current Oncol 2015; 22: 123-132.
Yen CF, Lee YY. Nail braces for severe paronychia induced by epidermal growth factor receptor inhibitors: an alternative to nail extraction. J Am Acad Dermatol 2017; 78: e89-e90.
Robert C, Sibaud V, Mateus C, et al. Nail toxicities induced by systemic anticancer treatments. Lancet Oncol 2015; 16: e181-e189.
Reidy JJ, Zarzour J, Thompson HW, et al. Effect of topical beta blockers on corneal epithelial wound healing in the rabbit. Br J Ophthalmol 1994; 78: 377-380.
Denda M, Fuziwara S, Inoue K. Beta2-adrenergic receptor antagonist accelerates skin barrier recovery and reduces epidermal hyperplasia induced by barrier disruption. J Invest Dermatol 2003; 121: 142-148.
Moreira C, Lopes S, Cruz MJ, et al. Topical timolol for the treatment of pyoderma gangrenosum. BMJ Case Rep 2017; 2017: bcr2016218589.
Larsen L, Tchanque-Fossuo CN, Gorouhi F, et al. Combination therapy of autologous adipose mesenchymal stem cell-enriched, high-density lipoaspirate and topical timolol for healing chronic wounds. J Tissue Eng Regen Med 2018; 12: 186-190.
Beroukhim K, Rotunda AM. Topical 0.5% timolol heals a recalcitrant irradiated surgical scalp wound. Dermatol Surg 2014; 40: 924-926.
Chiaverini C, Passeron T, Lacour JP. Topical timolol for chronic wounds in patients with junctional epidermolysis bullosa. J Am Acad Dermatol 2016; 75: e223-e224.
Yen CF, Hsu CK, Lu CW. Topical betaxolol for treating relapsing paronychia with pyogenic granuloma-like lesions induced by epidermal growth factor receptor inhibitors. J Am Acad Dermatol 2018; 78: e143-e144.
Moore RA, Straube S, Aldington D. Pain measures and cut-offs - 'no worse than mild pain' as a simple, universal outcome. Anaesthesia 2013; 68: 400-412.
Wnorowski AM, de Souza A, Chachoua A, et al. The management of EGFR inhibitor adverse events: a case series and treatment paradigm. Int J Dermatol 2012; 51: 223-232.
Chiriac A, Solovan C, Brzezinski P. Ingrown toenails (unguis incarnatus): Nail braces/bracing treatment. Proc (Bayl Univ Med Cent) 2014; 27: 145.
Melchionna R, Bellavia G, Romani M, et al. C/EBPgamma regulates wound repair and EGF receptor signaling. J Invest Dermatol 2012; 132: 1908-1917.
Pullar CE, Manabat-Hidalgo CG, Bolaji RS, et al. beta-Adrenergic receptor modulation of wound repair. Pharmacol Res 2008; 58: 158-164.
Smith C, Teitler M. Beta-blocker selectivity at cloned human beta 1- and beta 2-adrenergic receptors. Cardiovasc Drugs Ther 1999; 13: 123-126.
Davel AP, Fukuda LE, De Sa LL, et al. Effects of isoproterenol treatment for 7 days on inflammatory mediators in the rat aorta. Am J Physiol Heart Circ Physiol 2008; 295: H211-H219.
Piraccini BM, Alessandrini A, Dika E, et al. Topical propranolol 1% cream for pyogenic granulomas of the nail: open-label study in 10 patients. J Eur Acad Dermatol Venereol 2016; 30: 901-902.
Cubiro X, Planas-Ciudad S, Garcia-Muret MP, et al. Topical timolol for Paronychia and pseudopyogenic granuloma in patients treated with epidermal growth factor receptor inhibitors and capecitabine. JAMA Dermatol 2018; 154: 99-100.
Weibel L, Barysch MJ, Scheer HS, et al. Topical timolol for infantile hemangiomas: evidence for efficacy and degree of systemic absorption. Pediatr Dermatol 2016; 33: 184-190.
Vuori ML, Ali-Melkkila T, Kaila T, et al. Beta 1- and beta 2-antagonist activity of topically applied betaxolol and timolol in the systemic circulation. Acta Ophthalmol (Copenh) 1993; 71: 682-685.
Hirsh V. Afatinib (BIBW 2992) development in non-small-cell lung cancer. Future Oncol 2011; 7: 817-825.